The company’s $3 billion in earnings for the first quarter missed on both top and bottom line, according to BMO Capital Markets. Adding insult to injury, the FDA declined to approve a prefilled syringe of its ophthalmology cornerstone.
Regeneron Shares Tumble as Eylea Declines Make for a ‘Messy Quarter’ To Come